A day after Mabvax Therapeutics Holdings Inc. opted to forgo submission of a plan to regain compliance with Nasdaq listing standards, the San Diego-based company inked an exclusive sublicense with New York-based Y-mabs Therapeutics Inc. covering its bivalent ganglioside-based vaccine, known as MV-NB-02, to treat the rare pediatric cancer neuroblastoma.